The fight for dominance between Regeneron and Bayer’s big blockbuster eye drug Eylea and Roche’s rival Vabysmo is playing out ...

EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report fourth-quarter and full-year 2024 results on Feb. 4, 2025. The Zacks Consensus Estimate for fourth-quarter revenues is pegged at ...

The Federal Circuit left in place a pair of orders blocking two competitors of Regeneron Pharmaceuticals Inc. from marketing ...

Two biotech companies failed to reverse an order barring them from selling biosimilars of Regeneron’s eye disease drug Eylea ...

Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.94 billion, finds itself at a critical juncture as it navigates challenges to its flagship Eylea franchise while ...

San Francisco, California-- (Newsfile Corp. - January 30, 2025) - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) faces a securities fraud class action after shares of the company plunged $84.59 on Oct ...

If you purchased or acquired securities in Regeneron between November 2, 2023 and October 30, 2024 and would like to discuss ...

Regeneron’s lead drug, Eylea (aflibercept), is an anti-vascular endothelial growth factor inhibitor approved for various ophthalmology indications. To counter the ongoing decline in Eylea sales ...

Eylea (aflibercept) is a prescription drug that treats certain eye conditions. Eylea can cause side effects that range from mild to serious. An example includes cataracts, which may become a long ...

Earlier on Monday, Regeneron shared preliminary results from the fourth quarter that showed Eylea HD generated just $305 million in the U.S. It was a stunning drop-off from the $392 million the ...

Despite its historical success, Regeneron's Eylea franchise faces significant challenges from biosimilar competition. The company recently experienced a legal setback when a court denied its ...